Clopidogrel Monotherapy Appropriateness Checker Tool

Clinical calculation support · Verify results before clinical use

Clinical assessment

Review timing, bleeding and ischemic events, anticoagulation, and clopidogrel response before considering a regimen.

Decision support
This tool does not prescribe treatment. It distinguishes clopidogrel monotherapy from clopidogrel used with oral anticoagulation and highlights situations requiring clinician review.
Use elapsed time from the relevant index event. Enter 0 for the index presentation.
For example, atrial fibrillation, venous thromboembolism, or a mechanical valve.
Based on clinical assessment and, where appropriate, validated criteria such as ARC-HBR.
Select the most clinically relevant current course.
Availability alone does not determine the appropriate regimen.
Use available platelet-function or genotype information if obtained; testing is not mandatory for every patient.
Reset

Clinical context

Dual antiplatelet therapy with aspirin and an oral P2Y12 inhibitor is the default for at least 12 months after ACS in patients who are not at high bleeding risk. Selected patients after PCI may be considered for an abbreviated course to reduce bleeding risk, but the best single-antiplatelet strategy depends on the clinical setting.

Important distinctions

  • Clopidogrel monotherapy: clopidogrel is the only antiplatelet agent; this does not mean anticoagulation is being provided.
  • Clopidogrel plus oral anticoagulation: this is a combined antithrombotic regimen for patients with a separate indication for anticoagulation.
  • De-escalation: switching from ticagrelor or prasugrel to clopidogrel while continuing aspirin is not the same as stopping aspirin and using clopidogrel alone.
  • High bleeding risk: may support considering abbreviated therapy in selected patients, but does not automatically establish clopidogrel as the preferred single agent.

Limitations

This rule-based tool does not calculate a validated ischemic or bleeding score and does not replace review of PCI details, stent-thrombosis risk, ACS presentation, adherence, contraindications, drug interactions, or the reason for oral anticoagulation.

References

Rao SV, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes. J Am Coll Cardiol. 2025. DOI: 10.1016/j.jacc.2024.11.009
American Heart Association. 2025 Guideline for the Management of Patients With Acute Coronary Syndromes: Top Things to Know. Official guideline summary
Valgimigli M, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023. DOI: 10.1093/eurheartj/ehad191
Clinical disclaimer: For use by qualified healthcare professionals as an adjunct to clinical judgement. This tool is not a validated clinical prediction rule and must not be used alone to start, stop, or change antiplatelet or anticoagulant therapy. Active ischemia or major bleeding requires urgent clinical assessment. Confirm current local guidance and patient-specific contraindications before making treatment decisions.